The Triptans Novel Drugs for Migraine

by Humphrey, Patrick; Ferrari, Michel; Olesen, Jes

• ISBN13: 9780192632142
• ISBN10: 0192632140
• Edition: 1st
• Format: Hardcover
• Copyright: 2001-12-20
• Publisher: Oxford University Press

Summary

A new era in the treatment of migraine headache arrived with development of a revolutionary class of drugs known as the triptans.The book describes the development of this class of drugs, starting with the discovery of sumatriptin, covers the pharmacology and the mechanisms of action of the full range of triptans, before comparing their clinical efficacy and tolerability. Each drug is described by the company who produces itand then reviewed, based on experimental and clinical evidence, by independent scientists.This comprehensive review will provide clinicians with guidance on which triptan to select for which patient.The editors have gathered together the leading international experts to produce a book that will appeal to all neurologists and general physicians caring for headache patients as well as those with research interests in the field.

Table of Contents

List of Contributors	xi
Section I Background and early development	1	(54)
The discovery of sumatriptan and a new class of drug for the acute treatment of migraine	3	(8)
Patrick P.A. Humphrey
5-HT receptors in brain and vasculature	11	(12)
Richard Hargreaves
Margaret Beer
Structural and operational diversity of serotonin receptors: potential relevance to migraine pathophysiology and treatment	23	(12)
Graeme R. Martin
Characterisation of 5-HT1 receptor expression in human vasculature	35	(6)
Michael Mosley
Roy Mansfield
Aileen McHarg
5-HT1B and 5-HT1D receptor immunoreactivity co-localizes with sensory neurotransmitters in the human trigeminal ganglion	41	(5)
Mingyan Hou
Martin Kanje
Janos Tajti
Rolf Uddman
Lars Edvinsson
Upregulation of 5-HT1B/1D receptors during organ culture of cerebral arteries	46	(5)
Natalie L. Hoel
Jacob Hansen-Schwartz
Lars Edvinsson
Background and early development: discussion summary	51	(4)
Jes Olesen
Section II Pharmacology of the triptans	55	(68)
Clinical pharmacokinetics of the triptans: what are the important clinical issues?	57	(15)
David Millson
Pharmacodynamics of triptans	72	(8)
Pramod R. Saxena
Characteristics of different routes of administration	80	(11)
Carl G.H. Dahlof
Encapsulation of sumatriptan does not delay its absorption	91	(6)
K. Ashley Milton
D. Kleinermans
N. Scott
J.D.H. Cooper
Synergism of 5-HT1 and 5-HT2 receptors in sumatriptan-induced vasocontractile response in rabbit common carotid artery	97	(6)
Demet Akin
H. Ongun Onaran
Hakan Gurdal
Role of 5-HT1B and 5-HT1D receptors in sumatriptan-mediated vasocontractile response in rabbit common carotid artery	103	(6)
Demet Akin
Hakan Gurdal
Comparison of triptan-induced contractions in human cerebral versus coronary arteries	109	(5)
Erik Uddman
Lars Edvinsson
Pharmacological analysis of the contractile effects of eletriptan and sumatriptan on human isolated blood vessels	114	(6)
Remon W.M. van den Broek
Antoinette Maassen vandenbrink
Rene de Vries
Cees J. Avezaat
Pramod R. Saxena
Pharmacology of the triptans: discussion summary	120	(3)
Patrick P.A. Humphrey
Section III Antimigraine actions of the triptans	123	(58)
The importance of vasoconstriction in the mechanism of the antimigraine action of the triptans	125	(9)
W. Feniuk
Patrick P.A. Humphrey
Inhibition of neurogenic inflammation is most important	134	(8)
M. Gabriella Buzzi
Central nervous system effects are most important	142	(10)
Peter J. Goadsby
Do we really understand how the triptans work?	152	(6)
Jes Olesen
The relevance of hepatic intrinsic clearance and brain penetration on the doses used for 5-HT1B/1D agonists (triptans) in the treatment of migraine	158	(6)
Paul Morgan
Paul McCleverty
Aileen McHarg
K. Ashley Milton
In vivo serotonergic effects and extracellular brain levels of centrally and systemically administered eletriptan, zolmitriptan, and sumatriptan	164	(5)
Hans Rollema
David E. Johnson
Anne W. Schmidt
Aileen McHarg
Regulation of capsaicin-evoked CGRP release from rat dural sensory neurons in vitro	169	(4)
W. Feniuk
E. Jarvie
Patrick P.A. Humphrey
Arterial distensibility in ergotamine and sumatriptan abuse	173	(5)
Stefan Evers
Michael Barenbrock
Ingo W. Husstedt
Antimigraine actions of the triptans: discussion summary	178	(3)
Richard Hargreaves
Section IV Clinical efficacy and tolerability of the triptans	181	(102)
Sumatriptan: looking back and looking forward	183	(7)
Hank Mansbach
Zolmitriptan offers doctor and patient choices for effective treatment of migraine	190	(9)
Gerardo Torres
Rizatriptan: clinical update	199	(7)
Christopher Allen
Evidence against fight correlation between chest oppressive symptoms and ischaemic coronary changes after subcutaneous sumatriptan injection	206	(5)
Manami Tomita
Norihiro Suzuki
Hisaka Igarashi
Motoi Endo
Fumihiko Sakai
Alteration in cluster headache during subcutaneous administration of sumatriptan	211	(4)
Rachel Hering-Hanit
Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70 527 patient episodes	215	(7)
Harmut Gobel
Axel Heinze
Katja Heinze-Kuhn
V. Lindner
Consistency of pain relief over multiple migraine attacks following treatment with rizatriptan	222	(6)
Carl G.H. Dahlof
Richard B. Lipton
Christopher R. Lines
Mark S. Kramer
Scott A. Reines
Adam B. Polis
Michael D. Ferrari
Naratriptan: the gentle triptan	228	(8)
Reijo Salonen
Experience with eletriptan (Relpax™)	236	(11)
Neville Jackson
Almotriptan	247	(6)
Julio Pascual
Frovatriptan---simplifying clinical practice in migraine	253	(9)
Charlotte Keywood
Cardiovascular safety of frovatriptan in patients at high risk of or with known coronary artery disease during a migraine attack	262	(6)
A. Elkind
H.L. McDaris
L. Satin
Charlotte Keywood
Lack of clinically significant interactions between frovatriptan and ergotamine, propranolol, or moclobemide	268	(6)
P. Buchan
C. Ward
S.D. Oliver
A.J. Stewart
S. Freestone
Frovatriptan pharmacokinetics are unaffected during a migraine attack	274	(5)
P. Buchan
C. Ward
S. Zeig
Clinical efficacy and tolerability of the triptans: discussion summary	279	(4)
Michel D. Ferrari
Section V The triptans in clinical practice	283	(54)
Acute management of migraine: clinical trials of triptans versus other agents	285	(12)
Richard B. Lipton
Peter J. Goadsby
Which triptan for which patient?	297	(8)
Peer Tfelt-Hansen
The Framing 99 survey III: therapeutical behaviour of migraineurs	305	(4)
C. Lucas
M. Lanteri-Minet
L. Leroy
Migraine in France in 2000: therapeutical data	309	(5)
C. Lucas
M. Lanteri-Minet
J.P. Auray
G. Duru
G. Chazot
J.F. Dartigues
P. Henry
A. Pradalier
A. El Hasnaouia
A.F. Gaudin
The triptan threshold score: a score to help patients identify the best moment to take the triptan	314	(4)
Harmut Gobel
Axel Heinze
Katja Heinze-Kuhn
K. Austermann
D. Chryssafopoulos
R. Keil
Triptan plus NSAID with a long half-life: increase of efficacy and reduction of headache recurrence in acute migraine	318	(5)
Hartmut Gobel
Axel Heinze
Katja Heinze-Kuhn
Vera Zumbroich
Comparison of the triptans with other drugs in the development of drug-induced headache	323	(3)
Hartmut Gobel
Axel Heinze
Katja Heinze-Kuhn
Vera Zumbroich
An epidemiological study on the differences between sumatriptan and ergotamine overuse	326	(5)
Stefan Evers
Ingrid Gralow
Birgit Bauer
Birgit Suhr
Alexandra Buchheister
Ingo W. Husstedt
Overuse of new 5-HT agonists (zolmitriptan and naratriptan) in migraine patients: clinical features	331	(4)
M. Lanteri-Minet
H. Alchaar
P. Coullet
M. Chatel
The triptans in clinical practice: discussion summary	335	(2)
Peter J. Goadsby
Index	337